Summary
In the present experiment we tested the effects of L-DOPA upon dopamine (DA) efflux in vitro from superfused corpus striatal tissue fragments in medium containing reserpine. The purposes of this experiment were first, to evaluate the effects of differing infusion modes of L-DOPA upon DA efflux under conditions in which DA storage capacity has been diminished, and second, to compare this L-DOPA stimulated DA efflux with that of other putative DA secretagogues such as amphetamine and postassium. No differences were obtained in stimulated DA efflux between superfusions performed in the presence or absence of reserpine (10 μM) in the medium when L-DOPA (5 μM) was infused in a continuous (70 minute) mode during the superfusion. In contrast, a continuous infusion of either amphetamine (10 μM) or high potassium (30 mM) resulted in significantly greater stimulated DA efflux in superfusions performed with reserpine in the medium. In addition, when L-DOPA (5 μM) was administered for a brief 10-minute infusion period, a significantly greater stimulated DA efflux was obtained with superfusions containing reserpine in the medium. These results suggest that the mode of L-DOPA infusion may be an important factor in regulating DA release under conditions of diminished DA storage capacity.
Similar content being viewed by others
References
Bennett JP, Turk M, Landow E (1989) Continuous oral administration of L-dihydroxyphenylalanine (L-DOPA) solution to patients with advanced Parkinson's disease. Clin Neuropharmacol 12: 285–292
Brannan T, Bhardwaj A, Martinez-Tria J, Weinberger J, Yahr M (1990) Striatal L-DOPA metabolism studied in vivo in rats with nigrostriatal lesions. J Neural Transm [P-D Sect] 2: 15–22
Callaway CW, Kuczenski R, Segal DS (1989) Reserpine enhances amphetamine stereotypes without increasing amphetamine-induced changes in striatal dialysate dopamine. Brain Res 505: 83–90
Chase TN, Baronti F, Fabbrine G, Heuser IJ, Juncos JL, Mouradian MM (1989) Rationale for continuous dopaminergic therapy of Parkinson's disease. Neurology 39 [Suppl 2]: 7–10
Dluzen DE, Ramirez VD (1987) In vivo release of dopamine and its metabolites following a direct infusion of L-DOPA into the caudate nucleus of awake, freely behaving rats using a push-pull cannula. Neurosci Lett 82: 29–34
Dluzen DE, Ramirez VD (1989) Progesterone enhances L-DOPA-stimulated dopamine release from the caudate nucleus of freely behaving ovariectomized-estrogen primed rats. Brain Res 494: 122–128
Dluzen DE, McDermott JL (1991 a) The effect of long-term treatment with deprenyl on basal and L-DOPA evoked dopamine release from the corpus striatum of aged rats. J Neural Transm [Gen Sect] 85: 145–156
Dluzen DE, McDermott JL (1991 b) Striatal dopamine release in vitro from immature male rats shows enhanced responsiveness to pulsatile, but not continuous, infusions of L- DOPA. Dev Brain Res 62: 273–276
Dluzen DE, McDermott JL, Ramirez VD (1991) Changes in dopamine release in vitro from the corpus striatum of young versus aged rats as a function of infusion modes of L-DOPA, potassium and amphetamine. Exp Neurol 112: 153–160
Duvoisin R (1987) History of parkinsonism. Pharmacol Ther 32: 1–17
Elverfors A, Nissbrandt H (1991) Reserpine-insensitive dopamine release in the substantia nigra. Brain Res 557: 5–12
Enber TM, Susel Z, Juncos JL, Chase TN (1989) Continuous and intermittent levodopa differentially affect rotation induced by D-1 and D-2 dopamine agonists. Eur J Pharmacol 16: 291–298
German DC, McMillen BA, Sanghera MK, Saffer ST, Shore PA (1981) Effect of severe dopamine depletion on dopamine neuronal impulse flow and on tyrosine hydroxylase regulation. Brain Res Bull 6: 131–134
Juncos JL, Engber TM, Raisman R, Thirbout F, Ploska A, Agid Y, Chase TN (1989) Continuous and intermittent levodopa differentially affect basal ganglia function. Ann Neurol 25: 473–478
Kittner B, Brautigam M, Hesken H (1987) PC 12 cells: a model system for studying drug effects of dopamine synthesis and release. Arch Int Pharmacodyn 286: 181–194
Leenders KL, Palmer AJ, Quinn N, Clark JC, Firnau G, Garnett ES, Nahmais C, Jones T, Marsden CD (1986) Brain dopamine metabolism in patients with Parkinson's disease measured with positron emission tomography. J Neurol Neurosurg Psychiatry 49: 853–860
Lieberman A (1988) Dopamine agonists: new perspectives. Neuro View 4: 1–20
Marsden CD (1980) “On-off” phenomenon in Parkinson's disease. In: Rinne UK, et al (eds) Parkinson's disease: current progress, problems in management. Elsevier, Amsterdam, pp 241–254
Melamed E (1987) The failing efficacy of long term levodopa therapy in Parkinson's disease. I. Chemical features and neurochemical mechanisms. Neuro View 3: 1–16
Melamed E (1990) Interactions of exogenous L-DOPA with nigrostriatal dopaminergic neurons in Parkinson's disease. In: Streigler MB, et al (eds) Parkinson's disease: anatomy, pathology and therapy. Raven Press, New York, pp 61–66 (Adv Neurol 53)
Mouradian MM, Heuser IJE, Baronti F, Chase TN (1990) Modification of central do- paminergic mechanisms by continuous levodopa therapy for advanced Parkinson's disease. Ann Neurol 27: 18–23
Niddam R, Arbilla S, Scatton B, Dennis T, Langer SZ (1985) Amphetamine induced release of endogenous dopamine in vitro is not reduced following pretreatment with reserpine. Naunyn-Schmiedebergs Arch Pharmacol 329: 123–127
Ofori S, Bretton C, Hof P, Schorderet M (1986) Investigation of dopamine content, synthesis, and release in the rabbit retina in vitro. I. Effects of dopamine precursors, reserpine, amphetamine, and L-DOPA decarboxylase and monoamine oxidase inhibitors. J Neurochem 47: 1199–1206
Ramirez VD (1983) Hormones and striatal dopaminergic activity: a novel neuroendocrine model. In: Bhatnagar AJ (ed) The anterior pituitary gland. Raven Press, New York, pp 97–105
Ramirez VD, Kim K, Dluzen D (1985) Progesterone action on the LHRH and the nigrostriatal dopamine neuronal systems: in vitro and in vivo studies. In: Greep RO (ed) Recent progress in hormone research, vol 41. Academic Press, Orlando, pp 421–472
Strong R, Moore MA, Hale C, Wessels-Reiker M, Armbrecht HJ, Richardson A (1990) Modulation of tyrosine hydroxylase gene expression in the rat adrenal gland by age and reserpine. Brain Res 525: 126–132
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Dluzen, D.E., Kratko, F.T. L-DOPA infusion mode differentially affects corpus striatal dopamine efflux in the presence of reserpine. J. Neural Transmission 89, 197–207 (1992). https://doi.org/10.1007/BF01250672
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01250672